ClinicalTrials.gg
CompletedNCT03676725Updated Oct 6, 2022Results posted

Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD

An Early Phase 1 interventional study of Lidocaine gel in ADHD and PMS, sponsored by PhenoSolve, LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-06.

Sponsored by PhenoSolve, LLC · Early Phase 1, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
309th of 706
90 · median 70
Started
2019
with 31 others
Phase 1
48 of 807
3 open now
Registered
548th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 309th largest by enrollment of the 706 interventional ones that give a count, is one of 32 that started in 2019, is one of 48 in phase 1, and was the 548th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

This work will assess the prevalence in the general population of the ineffectiveness of the anesthetic Lidocaine compared to males with ADHD and females with ADHD with or without PMS.

Read the detailed description

Using a non-invasive, pain-free, taste-based approach to assess lidocaine effectiveness, the study will assess the frequency of ineffectiveness in the target population. We will use an identical protocol at two sites: Jacobi hospital and Boston Clinical Trials.

The controlled trial will assess the ability of lidocaine oral gel to block taste (e.g., sweet) in 100 teens and adults, half with a history of ADHD, and for females, we will compare the sub-groups with and without premenstrual syndrome (PMS).

This study will also be compared with a similar assessment among a specialized ADHD population (NCT03563573), that does not respond to existing medication..

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Exclusion Criteria for both arms:

(1) known adverse reactions to lidocaine; (2) ADHD, ADD, and other inattention disorders; (3) epilepsy, IQ \<80, severe head trauma, birth weight \<2270 grams, and severe autism; (4) treatment currently with potassium or potassium-elevating drugs such as renin-angiotensin-aldosterone blockers; (5) generalized anxiety disorders (but dental-specific anxiety will not be an exclusion because many of these individuals may be ones with anxiety because of painful dental experiences with lidocaine ineffectiveness); (6) mouth sores; (7) Ehlers Danlos syndrome, (8) red hair, and (9) current pregnancy.

05

Study design

Phase
Early Phase 1
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    All subjects

    All subjects get the lidocaine taste test

    Drug: Lidocaine gel

Interventions

  • Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)

    Also known as: Intervention

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Lidocaine Ineffectiveness

    Subjects will be asked to identify each taste and its intensity on a 0 (no taste) to 10 (very intense) scale before and after application of Lidocaine. Lidocaine effectiveness was quantitated as the reduction or elimination of taste by lidocaine compared to taste scores reported before lidocaine. For each of the four before/after pairs, the change in taste intensity was calculated, a weighted average score was computed. Incorrectly identified tastes were excluded. Scores of a reduction in taste ≥50% were considered to be lidocaine effective.

    Time frame: 30 minute visit, added on to a regular clinic visit

07

Results

Posted Jul 14, 2021

Participant flow

Participant flow — Overall Study
MilestoneMales Without ADHDMales With ADHDFemales Without ADHD and Without PMSFemales Without ADHD, But With PMSFemales With ADHD and Without PMSFemales With ADHD and With PMS
Started23142251511
Completed23142251511
Not completed000000

Outcome measures

PrimaryNumber of Subjects With Lidocaine Ineffectiveness

Subjects will be asked to identify each taste and its intensity on a 0 (no taste) to 10 (very intense) scale before and after application of Lidocaine. Lidocaine effectiveness was quantitated as the reduction or elimination of taste by lidocaine compared to taste scores reported before lidocaine. For each of the four before/after pairs, the change in taste intensity was calculated, a weighted average score was computed. Incorrectly identified tastes were excluded. Scores of a reduction in taste ≥50% were considered to be lidocaine effective.

Time frame:
30 minute visit, added on to a regular clinic visit
Reported as:
Count of participants · Participants
Number of Subjects With Lidocaine Ineffectiveness
ParticipantsMales Without ADHDMales With ADHDFemales Without ADHD and Without PMSFemales Without ADHD, But With PMSFemales With ADHD and Without PMSFemales With ADHD and With PMS
Lidocaine effective (gets numb)119165153
Lidocaine ineffective (does not get numb)1256008
Statistical analysis
  • Females Without ADHD and Without PMS vs Females Without ADHD, But With PMS vs Females With ADHD and Without PMS vs Females With ADHD and With PMS · Fisher Exact · p = 0.017 · Odds ratio (or): 5.17
  • Females Without ADHD and Without PMS vs Females Without ADHD, But With PMS vs Females With ADHD and Without PMS vs Females With ADHD and With PMS · Fisher Exact · p = 0.001 · Odds ratio (or): 16.0
  • Males Without ADHD vs Males With ADHD vs Females Without ADHD and Without PMS vs Females Without ADHD, But With PMS vs Females With ADHD and Without PMS vs Females With ADHD and With PMS · Fisher Exact · p = 0.8 · Odds ratio (or): 0.86

Adverse events

Collected over 1 day. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Subjects0/90 (0%)0/90 (0%)0/90 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Males Without ADHDMales With ADHDFemales Without ADHD and Without PMSFemales Without ADHD, But With PMSFemales With ADHD and Without PMSFemales With ADHD and With PMSTotal
<=18 years0000000
Between 18 and 65 years2314225151190
>=65 years0000000
Age, Continuous
Age, Continuous(years)Males Without ADHDMales With ADHDFemales Without ADHD and Without PMSFemales Without ADHD, But With PMSFemales With ADHD and Without PMSFemales With ADHD and With PMSTotal
Mean33 ± 7.627 ± 7.133 ± 6.433 ± 10.027 ± 6.130 ± 8.130 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Males Without ADHDMales With ADHDFemales Without ADHD and Without PMSFemales Without ADHD, But With PMSFemales With ADHD and Without PMSFemales With ADHD and With PMSTotal
Female00225151153
Male2314000037
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Males Without ADHDMales With ADHDFemales Without ADHD and Without PMSFemales Without ADHD, But With PMSFemales With ADHD and Without PMSFemales With ADHD and With PMSTotal
Hispanic or Latino53624424
Not Hispanic or Latino181116311766
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Males Without ADHDMales With ADHDFemales Without ADHD and Without PMSFemales Without ADHD, But With PMSFemales With ADHD and Without PMSFemales With ADHD and With PMSTotal
American Indian or Alaska Native0010001
Asian2110206
Native Hawaiian or Other Pacific Islander0000000
Black or African American82712222
White781049644
More than one race3110229
Unknown or Not Reported3220018
Region of Enrollment
Region of Enrollment(Participants)Males Without ADHDMales With ADHDFemales Without ADHD and Without PMSFemales Without ADHD, But With PMSFemales With ADHD and Without PMSFemales With ADHD and With PMSTotal
United States2314225151190
08

Study locations

2 sites
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
09

References and documents

Publications

  • Infante MA, Moore EM, Nguyen TT, Fourligas N, Mattson SN, Riley EP. Objective assessment of ADHD core symptoms in children with heavy prenatal alcohol exposure. Physiol Behav. 2015 Sep 1;148:45-50. doi: 10.1016/j.physbeh.2014.10.014. Epub 2014 Oct 23. PubMed 25447751 ↗
  • Levitt JO. Practical aspects in the management of hypokalemic periodic paralysis. J Transl Med. 2008 Apr 21;6:18. doi: 10.1186/1479-5876-6-18. Erratum In: J Transl Med. 2014;12:198. Dosage error in article text. PubMed 18426576 ↗
  • Nakai Y, Milgrom P, Mancl L, Coldwell SE, Domoto PK, Ramsay DS. Effectiveness of local anesthesia in pediatric dental practice. J Am Dent Assoc. 2000 Dec;131(12):1699-705. doi: 10.14219/jada.archive.2000.0115. PubMed 11143733 ↗
  • Segal MM. We cannot say whether attention deficit hyperactivity disorder exists, but we can find its molecular mechanisms. Pediatr Neurol. 2014 Jul;51(1):15-6. doi: 10.1016/j.pediatrneurol.2014.04.014. Epub 2014 Apr 18. No abstract available. PubMed 24938135 ↗
  • Segal MM, Rogers GF, Needleman HL, Chapman CA. Hypokalemic sensory overstimulation. J Child Neurol. 2007 Dec;22(12):1408-10. doi: 10.1177/0883073807307095. PubMed 18174562 ↗
  • Segal MM, Douglas AF. Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J Neurophysiol. 1997 Jun;77(6):3021-34. doi: 10.1152/jn.1997.77.6.3021. PubMed 9212254 ↗
  • Teicher MH, Polcari A, Fourligas N, Vitaliano G, Navalta CP. Hyperactivity persists in male and female adults with ADHD and remains a highly discriminative feature of the disorder: a case-control study. BMC Psychiatry. 2012 Nov 7;12:190. doi: 10.1186/1471-244X-12-190. PubMed 23134619 ↗
  • Mintz M, Badner V, Feldman LK, Mintz P, Saraghi M, Diaz J, Mezhebovsky I, Axelrod I, Gleeson J, Liu C, Smith C, Chow H, Zurakowski D, Segal MM. Lidocaine Ineffectiveness Suggests New Psychopharmacology Drug Target. Psychopharmacol Bull. 2022 Jun 27;52(3):20-30. PubMed 35815177 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We plan to submit for publication descriptions of what was accomplished, and the evaluations as described in the study, including the incidence of lidocaine ineffectiveness in those with ADHD and in the general population.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 9-12 months

Access criteria: Researchers

Data sharing details ↗ · phenosolve.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Mar 2020, 6 months.

Results were first posted in Jul 2021, 1 year 4 months after primary completion.

Of 21 industry-sponsored phase 1 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 2 months of starting (the median); a quarter within 1 and three quarters within 7. This study's 6 months is above that.

Counting every sponsor, half of 35 studies reached it within 9 months; a quarter within 2 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2018
First posted
Sep 19, 2018
StartActual
Aug 14, 2019
Primary completionActual
Mar 1, 2020
CompletionActual
Mar 1, 2020
Results first posted
Jul 14, 2021
Last update
Oct 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03676725
Lead sponsor
PhenoSolve, LLC
Collaborators
Jacobi Medical Center, Boston Clinical Trials
Responsible party
Sponsor
First posted
Sep 19, 2018
Start date
Aug 14, 2019
Primary completion
Mar 1, 2020
Completion
Mar 1, 2020
Results posted
Jul 14, 2021
Last update
Oct 6, 2022

Study contacts

Michael Segal, MD PhD
principal investigator · PhenoSolve, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion